<i>N</i><sup>2</sup>-Aroylanthranilamide Inhibitors of Human Factor Xa
作者:Ying K. Yee、Anne Louise Tebbe、Jared H. Linebarger、Douglas W. Beight、Trelia J. Craft、Donetta Gifford-Moore、Theodore Goodson、David K. Herron、Valentine J. Klimkowski、Jeffrey A. Kyle、J. Scott Sawyer、Gerald F. Smith、Jennifer M. Tinsley、Richard D. Towner、Leonard Weir、Michael R. Wiley
DOI:10.1021/jm990327e
日期:2000.3.1
Reversal of the A-ring amide link in 1,2-dibenzamidobenzene 1 (fXa K-ass = 0.81 x 10(6) L/mol) led to a series of human factor Xa (hfXa) inhibitors based on N-2-aroylanthranilamide 4. Expansion of the SAR around 4 showed that only small planar substituents could be accommodated in the A-ring for binding to the S1 site of hfXa. Bulky groups such as 4-isopropyl, 4-tert-butyl, and C-dimethylamino were favored in the B-ring to interact with the S4 site of hfXa. The central (C) ring containing a 5-methanesulfonamido group yielded greater activity than carbamoyl groups. Combining the beneficial features from the B- and C-ring SAR, compound 55 represents the most potent hfXa inhibitor in the N-2-aroylanthranilamide 4 series with hfXa K-ass = 58 x 10(6) L/mol (K-i = 11.5 nM).
Scaffold Identification of a New Class of Potent and Selective BCRP Inhibitors
We recently reported the synthesis and quantitativestructure–activityrelationships of a new breast cancer resistance protein (BCRP) inhibitor class. In the study presented herein, we investigated the possibility to better define the scaffold of this compound class by removing or modifying the aromatic ring A with various substituents selected on the basis of their electronic and lipophilic properties